Workflow
KMYY(600518)
icon
Search documents
康美药业(600518) - 康美药业关于召开2025年半年度业绩说明会的公告
2025-10-09 08:00
证券代码:600518 证券简称:康美药业 编号:临2025-033 会议召开方式:上证路演中心网络互动 投资者可于 2025 年 10 月 10 日(星期五)至 10 月 16 日(星期四)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 kangmei@kangmei.com.cn 进行提问。公司将在业绩说明会上对投资者普遍关注 的问题进行回答。 康美药业股份有限公司(以下简称公司)已于 2025 年 8 月 30 日发布公司 2025 年半年度报告,为便于广大投资者更全面深入地了解公司 2025 年半年度经 营成果、财务状况,公司计划于 2025 年 10 月 17 日(星期五)下午 15:00-16:00 举行 2025 年半年度业绩说明会,就投资者关心的问题进行交流。 一、业绩说明会类型 本次业绩说明会以网络互动形式召开,公司将针对 2025 年半年度经营成果、 财务指标的具体情况与投资者进行互动交流和沟通,在信息披露允许的范围内就 投资者普遍关注的问题进行回答。 康美药业股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在 ...
康美药业股份有限公司关于收到补偿款的公告
证券代码:600518 证券简称:康美药业 编号:临2025-032 康美药业股份有限公司 二、补偿的类型及其对上市公司的影响 根据《企业会计准则》等相关规定,公司上述获得的补偿款将一次性计入当期损益,预计对2025年度利 润将产生一定的积极影响。 ● 获得补偿款金额:461.32万元。 ● 对当期损益的影响:上述补偿款将一次性计入当期损益,最终对公司2025年度损益的影响以年度审计 机构确认的结果为准。 一、获得补偿款的基本情况 康美药业股份有限公司(以下简称公司)由于日常经营需要,与深圳市新安实业有限公司(以下简称出 租方)签订房屋租赁合同。后因深圳市轨道交通20号线二期项目推进,公司租赁房屋被纳入征收拆迁范 围。为配合出租方顺利完成房屋征收拆迁事宜,经双方友好协商一致,公司按约定完成房屋移交,且可 以取得相关补偿款。 公司于近日收到出租方支付的补偿款合计461.32万元,占公司最近一个会计年度经审计净利润的比例为 38.18%。 关于收到补偿款的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示: 上述补 ...
康美药业(600518.SH):收到补偿款461.32万元
Ge Long Hui A P P· 2025-09-30 12:31
格隆汇9月30日丨康美药业(600518.SH)公布,由于日常经营需要,与深圳市新安实业有限公司(简称出 租方)签订房屋租赁合同。后因深圳市轨道交通20号线二期项目推进,公司租赁房屋被纳入征收拆迁范 围。为配合出租方顺利完成房屋征收拆迁事宜,经双方友好协商一致,公司按约定完成房屋移交,且可 以取得相关补偿款。公司于近日收到出租方支付的补偿款合计461.32万元,占公司最近一个会计年度经 审计净利润的比例为38.18%。 ...
康美药业(600518) - 康美药业关于收到补偿款的公告
2025-09-30 11:01
证券代码:600518 证券简称:康美药业 编号:临2025-032 康美药业股份有限公司 关于收到补偿款的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 获得补偿款金额:461.32 万元。 公司于近日收到出租方支付的补偿款合计 461.32 万元,占公司最近一个会 计年度经审计净利润的比例为 38.18%。 二、补偿的类型及其对上市公司的影响 根据《企业会计准则》等相关规定,公司上述获得的补偿款将一次性计入当 期损益,预计对 2025 年度利润将产生一定的积极影响。 上述补偿具体的会计处理以及最终对公司 2025 年度损益的影响以年度审计 机构确认的结果为准。敬请广大投资者注意投资风险。 特此公告。 康美药业股份有限公司董事会 二〇二五年十月一日 1 对当期损益的影响:上述补偿款将一次性计入当期损益,最终对公司 2025 年度损益的影响以年度审计机构确认的结果为准。 一、获得补偿款的基本情况 康美药业股份有限公司(以下简称公司)由于日常经营需要,与深圳市新安 实业有限公司(以下简称出租方)签订房屋租赁 ...
严监严管持续优化资本市场新生态
Zheng Quan Ri Bao· 2025-09-28 16:08
Core Viewpoint - The China Securities Regulatory Commission (CSRC) is intensifying its regulatory enforcement against financial fraud and information disclosure violations, aiming to enhance market integrity and investor confidence [1][2][3]. Regulatory Framework - Recent legal reforms, including the new Securities Law and related regulations, have established a robust regulatory framework for capital markets, providing a solid basis for enforcement actions [2][3]. - The CSRC has issued over 2,200 administrative penalties for financial fraud and market manipulation during the 14th Five-Year Plan period, with fines totaling 41.4 billion yuan, marking increases of 58% and 30% respectively compared to the previous five-year period [2][3]. Enforcement Actions - The CSRC is focusing on severe violations such as financial fraud and insider trading, with notable cases leading to significant penalties, including a 2.25 billion yuan fine against Zhongke Huayuan Titanium Co., Ltd. for compliance violations [3][4]. - Since last year, the CSRC has investigated 67 delisted companies for illegal activities, with 33 cases referred for potential criminal prosecution [3][4]. Investor Protection - The regulatory bodies are enhancing investor protection mechanisms, including the introduction of new judicial interpretations and multi-faceted dispute resolution frameworks to support investor rights [5][6]. - Landmark cases, such as the special representative litigation against Kangmei Pharmaceutical, have resulted in substantial compensation for investors, demonstrating the effectiveness of the new protective measures [5][6]. Comprehensive Accountability - The CSRC is promoting a multi-layered accountability system that integrates administrative, civil, and criminal responsibilities to strengthen deterrence against securities violations [8][9]. - Over the past five years, the CSRC has referred more than 700 cases to law enforcement, leading to serious criminal accountability for numerous offenders [9]. Future Directions - Experts suggest that future regulatory efforts should focus on precise enforcement against financial fraud while ensuring that intermediary institutions fulfill their responsibilities as gatekeepers [4][6]. - There is a call for a "one-stop" platform for investor rights protection, integrating various forms of dispute resolution to facilitate easier access for small investors [7].
证监会主席吴清:坚决维护市场平稳运行 投资者信心和市场预期明显改善
Zheng Quan Ri Bao Wang· 2025-09-22 09:58
Group 1 - The core viewpoint emphasizes the importance of building a "safe, standardized, transparent, open, vibrant, and resilient" capital market, highlighting risk prevention and strong regulation as priorities [1] - The regulatory body is committed to maintaining market stability through comprehensive monitoring and early warning systems, as well as enhancing cross-market risk prevention mechanisms [1] - The bond default rate in the exchange market remains low at around 1%, indicating effective risk control measures [1] Group 2 - Regulatory enforcement has been significantly strengthened, focusing on financial fraud and establishing a comprehensive deterrent system against such violations [2] - Major penalties have been imposed for financial misconduct, including a record fine of 4.175 billion yuan against Evergrande and 325 million yuan against its auditing firm [2] - Over 700 cases have been referred to law enforcement for criminal accountability in the past five years, reflecting a rigorous approach to legal enforcement [2] Group 3 - Investor protection measures have been enhanced, with new regulations on share reduction, quantitative trading, and short selling being implemented [3] - Landmark cases have resulted in substantial compensation for investors, including approximately 2.46 billion yuan for the Kangmei Pharmaceutical case and 1.09 billion yuan for the Zijing Storage case [3] - A comprehensive investor protection system is being developed, ensuring accountability and quality evaluation for intermediary institutions [3]
中药板块9月19日跌0.81%,康美药业领跌,主力资金净流出10.76亿元
从资金流向上来看,当日中药板块主力资金净流出10.76亿元,游资资金净流入2.72亿元,散户资金净流 入8.04亿元。中药板块个股资金流向见下表: | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入(元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 300878 维康药业 | | 3055.24万 | 13.01% | 808.07万 | 3.44% | -3863.30万 | -16.45% | | 600572 | 康恩贝 | 1028.82万 | 7.44% | 336.93万 | 2.44% | -1365.75万 | -9.87% | | 000423 | 东阿阿胶 | 766.16万 | 2.06% | -1729.21万 | -4.64% | 963.05万 | 2.59% | | 300391 | *ST长药 | 358.88万 | 7.94% | -212.58万 | -4.70% | -146.30万 | -3.24% | | 002412 汉森制药 ...
中药板块9月15日跌0.37%,ST香雪领跌,主力资金净流出4.7亿元
Market Overview - The Chinese medicine sector experienced a decline of 0.37% on September 15, with ST Xiangxue leading the drop [1] - The Shanghai Composite Index closed at 3860.5, down 0.26%, while the Shenzhen Component Index rose by 0.63% to 13005.77 [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Wanbangde (002082) with a closing price of 11.33, up 10.00% [1] - Kangmei Pharmaceutical (600518) at 2.18, up 4.81% [1] - Zhongheng Group (600252) at 2.88, up 3.97% [1] - Conversely, ST Xiangxue (300147) saw a significant decline of 4.39%, closing at 10.66 [2] - Other notable decliners included: - Enwei Pharmaceutical (301331) down 3.25% [2] - Zhendong Pharmaceutical (300158) down 2.97% [2] Trading Volume and Capital Flow - The Chinese medicine sector recorded a net outflow of 470 million yuan from institutional investors, while retail investors saw a net inflow of 398 million yuan [2] - The trading volume for major stocks included: - Kangmei Pharmaceutical with a trading volume of 9.5463 million shares and a transaction value of 2.086 billion yuan [1] - Wanbangde with a trading volume of 414,700 shares and a transaction value of 448 million yuan [1] Capital Inflow Analysis - Major stocks with significant net inflows from institutional investors included: - Kangmei Pharmaceutical with a net inflow of 18.7 million yuan [3] - Wanbangde with a net inflow of 67.5 million yuan [3] - Conversely, stocks like Zhongheng Group and Panzhong Pharmaceutical experienced net outflows from institutional investors [3]
中药板块9月12日跌0.56%,千金药业领跌,主力资金净流出6.42亿元
Market Overview - On September 12, the Chinese medicine sector declined by 0.56%, with Qianjin Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3883.69, up 0.22%, while the Shenzhen Component Index closed at 12996.38, up 0.13% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Wanbangde (002082) with a closing price of 10.25, up 3.64% on a trading volume of 228,400 shares and a turnover of 230 million yuan [1] - Jiuzhitang (000989) closed at 10.91, up 2.83% with a trading volume of 212,800 shares and a turnover of 233 million yuan [1] - Kangmei Pharmaceutical (600518) closed at 2.07, up 2.48% with a trading volume of 4,321,600 shares and a turnover of 891 million yuan [1] - Conversely, significant decliners included: - Qianjin Pharmaceutical (600479) closed at 11.05, down 1.60% with a trading volume of 115,400 shares and a turnover of 128 million yuan [2] - Jianmin Group (600976) closed at 42.45, down 1.12% with a trading volume of 18,100 shares and a turnover of 77 million yuan [2] - Hansen Pharmaceutical (002412) closed at 6.74, down 1.03% with a trading volume of 133,300 shares and a turnover of 89 million yuan [2] Capital Flow - The Chinese medicine sector experienced a net outflow of 642 million yuan from institutional investors, while retail investors saw a net inflow of 448 million yuan [2] - The following stocks had notable capital flows: - Kangmei Pharmaceutical had a net inflow of 65.97 million yuan from institutional investors, but a net outflow of 14.99 million yuan from retail investors [3] - Jiuzhitang saw a net inflow of 33.21 million yuan from institutional investors, with a net outflow of 16.66 million yuan from retail investors [3] - Wanbangde had a net inflow of 30.43 million yuan from institutional investors, but also faced a net outflow of 19.37 million yuan from retail investors [3]
中药板块9月1日涨0.75%,振东制药领涨,主力资金净流出2970.85万元
Market Overview - The Chinese medicine sector rose by 0.75% on September 1, with Zhendong Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3875.53, up 0.46%, while the Shenzhen Component Index closed at 12828.95, up 1.05% [1] Top Gainers in Chinese Medicine Sector - Zhendong Pharmaceutical (300158) closed at 9.21, up 6.11% with a trading volume of 1.2136 million shares and a turnover of 1.101 billion yuan [1] - Qidi Pharmaceutical (000590) closed at 12.33, up 4.14% with a trading volume of 140,800 shares and a turnover of 174 million yuan [1] - Kangmei Pharmaceutical (600518) closed at 2.12, up 3.92% with a trading volume of 5.5195 million shares and a turnover of 1.165 billion yuan [1] Top Losers in Chinese Medicine Sector - Tianmu Pharmaceutical (600671) closed at 19.44, down 1.87% with a trading volume of 86,000 shares and a turnover of 170 million yuan [2] - Jilin Aodong (000623) closed at 20.13, down 1.66% with a trading volume of 284,000 shares and a turnover of 573 million yuan [2] - *ST Changyao (300391) closed at 4.19, down 1.64% with a trading volume of 86,000 shares and a turnover of 36.1 million yuan [2] Capital Flow Analysis - The Chinese medicine sector experienced a net outflow of 29.7085 million yuan from institutional investors, while retail investors saw a net inflow of 253 million yuan [2][3] - Notable net inflows from retail investors were observed in Yunnan Baiyao (000538) with 436.788 million yuan and in Zhongsheng Pharmaceutical (002317) with 82.0845 million yuan [3] Individual Stock Capital Flow - Yunnan Baiyao (000538) had a net inflow of 188 million yuan from institutional investors, but a net outflow of 144 million yuan from speculative funds [3] - Zhongsheng Pharmaceutical (002317) saw a net inflow of 54.7945 million yuan from institutional investors, while retail investors experienced a net outflow of 82.0845 million yuan [3] - Dong'e Ejiao (000423) had a net inflow of 53.6307 million yuan from institutional investors, with a net outflow of 40.1030 million yuan from speculative funds [3]